Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era Academic Article uri icon

Overview

MeSH Major

  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms

abstract

  • Few patients will die from prostate cancer within 15 years of radical prostatectomy, despite the presence of adverse clinical features. This favorable prognosis may be related to the effectiveness of radical prostatectomy (with or without secondary therapy) or the low lethality of screen-detected cancers. Given the limited ability to identify contemporary patients at substantially elevated risk of PCSM on the basis of clinical features alone, the need for novel markers specifically associated with the biology of lethal prostate cancer is evident.

publication date

  • September 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3651598

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.18.2501

PubMed ID

  • 19636023

Additional Document Info

start page

  • 4300

end page

  • 5

volume

  • 27

number

  • 26